UGT1A1 and familial pancreatic carcinoma: However, a multicenter retrospective study of FOLFIRINOX in advanced pancreatic cancer patients with double-variant type UGT1A1*28 and *6 polymorphism was conducted by our colleagues and they recommend that the initial dose of irinotecan should be further reduced to ≤ 120 mg/m2 of body surface area in such patients22.